Neuromics

Neuromics We provide 2&3D Cell Based Assays, media and supplements (FBS) researching diseases and inventing new and better therapies. We stand behind our products.

We are in the business of supporting those we keep us well and alive longer. We specialize in providing reagents and methods for the Neuroscience, Stem Cell and Regenerative Medicine Research Community. We serve scientists doing basic research and drug discovery in Neurodegenerative Diseases, Pain, Autoimmune Diseases and Cancer. Our unique value is based on providing reagents that are thoroughly

tested and characterized. If our reagents or cells do not meet expectations, we will fix it. We will either send equivalent replacement quantities or refund your money. Your satisfaction and feedback are important to our mutual success.

🧬 New graduates step forward to advance cancer researchNeuromics congratulates Magdalena Murray and Santiago Sanchezhttp...
06/24/2026

🧬 New graduates step forward to advance cancer research

Neuromics congratulates Magdalena Murray and Santiago Sanchez

https://tinyurl.com/Cancer-Research-Stanford

"Cancer is often treated only after it becomes visible. But some of the most important discoveries happen earlier, at the cellular level, where the molecular processes that drive health and disease first unfold."

✅ "Magdalena Murray, PhD, and Santiago Sanchez, MD, PhD candidate, have spent years working in this critical space. Murray aims to kill cancer cells by exploiting their vulnerabilities. Sanchez hopes to improve early detection and prevention by understanding how a critical chromosome structure is linked to disease. Though they ask different questions, both are working to uncover new ways to combat cancer."
🔎Please consider following our Showcase Page-https://tinyurl.com/News-Neuromics
🧠 Please check out our AI Assistant-https://tinyurl.com/Check-out-AssayIQ
,

The Stanford Cancer Biology PhD Program is preparing the next generation of scientists to tackle some of cancer research’s most challenging questions.

🛄 Neuromics (www.neuromics.com) Organoid Induction, Growth, and Maintenance Media🟩  Organoids offer researchers 3D, self...
06/23/2026

🛄 Neuromics (www.neuromics.com) Organoid Induction, Growth, and Maintenance Media
🟩 Organoids offer researchers 3D, self-assembling cellular clusters that mimic the architecture and functionality of real human organs. They bridge the gap between traditional 2D cell cultures and living animal models, allowing for more accurate, human-specific testing.

▶️ Neuromics Organoid Media are chemically defined, serum-free, animal component–free media optimized and formulated to support the self-organization of endothelial cells, pericytes, and mesenchymal cells into complex 3D structures that recapitulate the architecture and function of human blood vessels, including capillary networks and
arteriole-like structures.
https://www.neuromics.com/organoid-induction-growth-and-maintenance-media

🛄 Neuromics (www.neuromics.com) Organoid Induction, Growth, and Maintenance Media🔷 Organoids offer researchers 3D, self-...
06/23/2026

🛄 Neuromics (www.neuromics.com) Organoid Induction, Growth, and Maintenance Media
🔷 Organoids offer researchers 3D, self-assembling cellular clusters that mimic the architecture and functionality of real human organs. They bridge the gap between traditional 2D cell cultures and living animal models, allowing for more accurate, human-specific testing.

▶️ Neuromics Organoid Media are chemically defined, serum-free, animal component–free media optimized and formulated to support the self-organization of endothelial cells, pericytes, and mesenchymal cells into complex 3D structures that recapitulate the architecture and function of human blood vessels, including capillary networks and arteriole-like structures.

Neuromics, Vascular Organoid Media is designed to induce and grow physiologically relevant blood vessel organoids—easily and with high yield—for your tissue repair and regeneration studies or to model vascular disease in vitro. The media drives efficient and reproducible generation of blood vess...

Courtesy of RFK, jr's, Centers for Disease Control and Prevention, and U.S. Department of Health and Human Services (HHS...
06/21/2026

Courtesy of RFK, jr's, Centers for Disease Control and Prevention, and U.S. Department of Health and Human Services (HHS) vaccine propaganda.
https://tinyurl.com/RFK-JR-MEASLES-UTAH
"While most recover, some — particularly young babies, pregnant people, and those with weak immune systems — are at higher risk of developing dangerous complications such as pneumonia, brain swelling, blindness, or even death. Even healthy people can develop issues years down the road, including a rare but fatal degenerative brain disease that can manifest about a decade after infection."

"The measles vaccine is safe and 97% protective after two doses."

PostSee new postsConversationNeuromicsHighlights Courtesy of  💉 , and the   have no understanding of immunology, nor the...
06/21/2026

Post

See new posts
Conversation
Neuromics

Highlights Courtesy of


💉

, and the

have no understanding of immunology, nor the damage long does to our immune systems.
📰source: Ip, S., et al. COVID-19 vaccination and cardiovascular events: a nationwide cohort study of 45.7 million adults in England. Nature Communications.
✅ A study of 46 million adults reveals COVID-19 vaccinations significantly reduced the risk of heart attacks and strokes.
➡️ Although rare side effects such as myocarditis were tracked, they remained exceptionally uncommon and were vastly outweighed by the dangers of the virus itself. In contrast, contracting
➡️ COVID-19 is known to significantly spike the risk of serious heart problems and blood clots.
➡️ These findings offer powerful support for the safety of vaccination programs, confirming that the vaccines do more than just prevent respiratory illness—they actively safeguard the circulatory system.

06/20/2026

💉 Robert F. Kennedy, Jr , and the CDC have no understanding of immunology, nor the damage long does to our immune systems.

📰source: Ip, S., et al. COVID-19 vaccination and cardiovascular events: a nationwide cohort study of 45.7 million adults in England. Nature Communications.

✅ A study of 46 million adults reveals COVID-19 vaccinations significantly reduced the risk of heart attacks and strokes.
➡️ Although rare side effects such as myocarditis were tracked, they remained exceptionally uncommon and were vastly outweighed by the dangers of the virus itself. In contrast, contracting
➡️ COVID-19 is known to significantly spike the risk of serious heart problems and blood clots.
➡️ These findings offer powerful support for the safety of vaccination programs, confirming that the vaccines do more than just prevent respiratory illness—they actively safeguard the circulatory system. U.S. Department of Health and Human Services

🧠 The GSK2 and Alzheimer's DiseaseResearchers at ETH Zurich have uncovered a new biological pathway that may help explai...
06/15/2026

🧠 The GSK2 and Alzheimer's Disease
Researchers at ETH Zurich have uncovered a new biological pathway that may help explain how Alzheimer's progresses and how it could potentially be slowed.

At the center of the discovery is GRK2, an enzyme that normally helps brain cells respond to stress. But in Alzheimer's, GRK2 can become inactivated and clump together into toxic aggregates. These aggregates accumulate on mitochondria, the cell's powerhouses, blocking their pores and starving neurons of the energy they need to survive.

The damage doesn't stop there. The team found that inactive GRK2 also accelerates the production of amyloid-beta, one of Alzheimer's hallmark proteins. That amyloid-beta places even more stress on neurons, triggering additional GRK2 inactivation and creating a self-perpetuating vicious cycle of degeneration.

To interrupt this loop, researchers developed Compound 10, a molecule designed to prevent GRK2 aggregation.
In mouse models, Compound 10:
🔬 Preserved mitochondrial function
🧠 Reduced amyloid-beta accumulation
⚡ Delayed nerve cell death
❤️ Improved heart function
🐭 Extended survival
Perhaps most remarkable is the timeline behind this work. The project began nearly 20 years ago using human brain tissue samples from Ain Shams University Hospital in Cairo. Because Alzheimer's is an age-related disease, many experiments required older mice, which meant each study took years to complete.

Interesting results courtesy of Shining ScienceThis is a pre-clinical study. Hope? Yes. Clinical studies required. 📰 sou...
06/11/2026

Interesting results courtesy of Shining Science
This is a pre-clinical study. Hope? Yes. Clinical studies required.
📰 source: Murdock, M. H., et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature, 627(8002), 149-156.
Highlights:
🧠 A noninvasive treatment using light and sound shown to trigger the brain’s natural waste-clearance system to combat Alzheimer's disease.
✅ In a groundbreaking preclinical study funded by the National Institute on Aging (NIA), researchers from MIT, Boston University, and Westlake University in China have discovered that noninvasive light and sound stimulation can significantly reduce levels of toxic amyloid proteins in the brain.
✅ This sensory stimulation effectively tapped into the brain’s glymphatic system—its internal waste-disposal network—prompting cells called astrocytes to expand, flush out debris, and clear the destructive plaques historically associated with Alzheimer’s disease.
➡️ These promising results suggest that simple, noninvasive sensory therapy could act as a potent tool to keep our brain's plumbing running smoothly, offering a highly accessible avenue for treating Alzheimer’s and other protein-accumulating neurological disorders.
Stay tuned.. Neuromics will stay informed as noninvasive therapies move into Clinical Studies.
🔎Please consider following our Showcase Page-https://tinyurl.com/News-Neuromics
🧠 Please check out our AI Assistant-https://tinyurl.com/Check-out-AssayIQ

📰Neuromics' Pancreatic CAFS used in Phase 1 Trial➡️ Adenosine Biology and Pancreatic Cancer and Tumor Microenvironment (...
06/10/2026

📰Neuromics' Pancreatic CAFS used in Phase 1 Trial

➡️ Adenosine Biology and Pancreatic Cancer and Tumor Microenvironment (TME)

✅ Researchers from Arcus Biosciences, UCLA, Columbia, Stephenson Cancer Center, MD Anderson Cancer Center, Sarah Cannon Research Institute, University of Wisconsin, and NYU Langone used Neuromics' Pancreatic Cancer-Associated Fibroblasts (CAFS) https://neuromics.com/CAF118 to conduct a Phase 1 Study.

"Quemliclustat and chemotherapy with or without Zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial."
https://nature.com/articles/s41591-026-04283-z

🧬 Image: a, Venn diagrams showing genes upregulated via RNA-seq experiments in four cell types comprising components of the TME (PANC-1, MIA PaCa-2, CAF, and CD8+ T cells) and inhibited in two cell types (PANC-1 and MIA PaCa-2). A total of 15 genes were upregulated by AMP and inhibited by quemliclustat. Differentially expressed genes are defined as an increase or decrease of 50% log2 fold change with FDR ≤ 0.05. b, Heatmap of log2 fold change of RT−PCR values for NR4A family genes treated with adenosine-generating conditions or adenosine 2a receptor/adenosine 2b receptor agonist conditions and their corresponding inhibitors in expanded cell types in the TME. c, NR4A family genes can be upregulated to varying degrees in cell types compared to human PDAC in response to chemotherapy.

Elevated adenosine levels in the TME suppress inflammation and immune function, markedly limiting the ability of the immune system to destroy tumor cells.

Address

5325 West 74th Street Suite 8
Edina, MN
55439

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Alerts

Be the first to know and let us send you an email when Neuromics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share